Teva’s inhaler patent should be delisted, FTC says
The Federal Trade Commission said in a court filing that drugmaker Teva has improperly listed patents in the Food and Drug Administration’s Orange Book and urged the court to order those...To view the full article, register now.
Already a subscriber? Click here to view full article